Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006133:Growth Substances / Q000097:blood*; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013936:Thymidine / Q000378:metabolism
D000970:Antineoplastic Agents; D006133:Growth Substances; D003561:Cytarabine; D003520:Cyclophosphamide; D013936:Thymidine; D003630:Daunorubicin